PMC:7274968 / 4310-4574 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"72","span":{"begin":150,"end":168},"obj":"Gene"},{"id":"73","span":{"begin":170,"end":172},"obj":"Gene"},{"id":"74","span":{"begin":176,"end":180},"obj":"Gene"},{"id":"79","span":{"begin":58,"end":66},"obj":"Species"},{"id":"85","span":{"begin":88,"end":110},"obj":"Disease"}],"attributes":[{"id":"A72","pred":"tao:has_database_id","subj":"72","obj":"Gene:2069"},{"id":"A73","pred":"tao:has_database_id","subj":"73","obj":"Gene:2069"},{"id":"A74","pred":"tao:has_database_id","subj":"74","obj":"Gene:2064"},{"id":"A79","pred":"tao:has_database_id","subj":"79","obj":"Tax:9606"},{"id":"A85","pred":"tao:has_database_id","subj":"85","obj":"MESH:D001943"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In 2 out of 22 centers (9%), radiotherapy was omitted for patients aged ≥65 years, with invasive breast cancer \u003c30 mm, with clear margins, grade 1–2, estrogen receptors (ER)+, HER2−, and node negative disease, who were planned for treatment with endocrine therapy."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T8","span":{"begin":97,"end":103},"obj":"Body_part"},{"id":"T9","span":{"begin":150,"end":158},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma9601"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma83376"}],"text":"In 2 out of 22 centers (9%), radiotherapy was omitted for patients aged ≥65 years, with invasive breast cancer \u003c30 mm, with clear margins, grade 1–2, estrogen receptors (ER)+, HER2−, and node negative disease, who were planned for treatment with endocrine therapy."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T4","span":{"begin":97,"end":103},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0000310"}],"text":"In 2 out of 22 centers (9%), radiotherapy was omitted for patients aged ≥65 years, with invasive breast cancer \u003c30 mm, with clear margins, grade 1–2, estrogen receptors (ER)+, HER2−, and node negative disease, who were planned for treatment with endocrine therapy."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T24","span":{"begin":88,"end":110},"obj":"Disease"},{"id":"T25","span":{"begin":97,"end":110},"obj":"Disease"},{"id":"T26","span":{"begin":104,"end":110},"obj":"Disease"}],"attributes":[{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0006256"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0007254"},{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"In 2 out of 22 centers (9%), radiotherapy was omitted for patients aged ≥65 years, with invasive breast cancer \u003c30 mm, with clear margins, grade 1–2, estrogen receptors (ER)+, HER2−, and node negative disease, who were planned for treatment with endocrine therapy."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T55","span":{"begin":12,"end":14},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T56","span":{"begin":97,"end":103},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"T57","span":{"begin":150,"end":168},"obj":"http://purl.obolibrary.org/obo/PR_000007204"},{"id":"T58","span":{"begin":170,"end":172},"obj":"http://purl.obolibrary.org/obo/PR_000007204"}],"text":"In 2 out of 22 centers (9%), radiotherapy was omitted for patients aged ≥65 years, with invasive breast cancer \u003c30 mm, with clear margins, grade 1–2, estrogen receptors (ER)+, HER2−, and node negative disease, who were planned for treatment with endocrine therapy."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T5","span":{"begin":150,"end":158},"obj":"Chemical"},{"id":"T6","span":{"begin":246,"end":255},"obj":"Chemical"}],"attributes":[{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_50114"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_24621"}],"text":"In 2 out of 22 centers (9%), radiotherapy was omitted for patients aged ≥65 years, with invasive breast cancer \u003c30 mm, with clear margins, grade 1–2, estrogen receptors (ER)+, HER2−, and node negative disease, who were planned for treatment with endocrine therapy."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T13","span":{"begin":97,"end":110},"obj":"Phenotype"}],"attributes":[{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0003002"}],"text":"In 2 out of 22 centers (9%), radiotherapy was omitted for patients aged ≥65 years, with invasive breast cancer \u003c30 mm, with clear margins, grade 1–2, estrogen receptors (ER)+, HER2−, and node negative disease, who were planned for treatment with endocrine therapy."}

{"project":"LitCovid-sentences","denotations":[{"id":"T36","span":{"begin":0,"end":264},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In 2 out of 22 centers (9%), radiotherapy was omitted for patients aged ≥65 years, with invasive breast cancer \u003c30 mm, with clear margins, grade 1–2, estrogen receptors (ER)+, HER2−, and node negative disease, who were planned for treatment with endocrine therapy."}